Table 1. The Harwell Ageing screen phenotyping pipeline.
Test | Phenotypic Area | Group | Age (weeks) |
---|---|---|---|
ECG | Cardiac | All | 12 |
SHIRPA | Neurological | Females (males) | 13, 66 |
Grip strength | Musculoskeletal/neurological | All | 13, 66 |
Slit lamp/opthalmoscope | Vision | All | 15, 49, 65, (73) |
Optokinetic drum | Vision/neurological | All | 15, 49, 65, (73) |
Click box | Hearing | Non ahl* | 14, 26, 39, 50 |
Auditory brainstem response+click stimulus | Hearing | Non ahl* | 14, 39 |
Echo-MRI | Growth/body composition | Males (females) | 16, 27, 51, 71 |
DEXA | Musculoskeletal/body composition | Females (males) | 16, 51, |
X-ray | Musculoskeletal | Females (males) | 16, 51, 74 |
Pupillometry | Vision/neurobehaviour | All | 18, 68 |
Sleep tracking | Neurobehaviour | Females (males) | 18, 68 |
Clinical chemistry | Pathology | Females (males) | 28, 53, 80 |
Fasted bleed | Diabetes/metabolism | Males (females) | 17, 28, 52, 80 |
Fasted insulin | Diabetes/metabolism | Males (females) | 33, 57, 72 |
IPGTT | Diabetes/metabolism | Males (females) | 33, 57, 72 |
ECG, electrocardiogram; DEXA, dual energy X-ray analysis; IPGTT, intraperitoneal glucose tolerance test; MRI, magnetic resonance imaging; SHIRPA, SmithKline Beecham, Harwell, Imperial College and Royal London Hospital phenotype assessment.
A summary and timetable of the core phenotyping tests in the Harwell Ageing Screen, indicating screening time points. In addition to the documented phenotype tests mice are weighed every 3 months up until the age of 12 months and then monthly from 12 months onwards. For the tests where a single sex was initially tested the other sex was screened when outliers were suspected. The screening timetable is flexible and additional screens can be added to confirm outliers depending on the phenotype detected.
*G3 mice mothered by G2 females that do not carry the Cdh23ahl allele.